Henry Schein Company Profile (NASDAQ:HSIC)

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Henry Schein's stock split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly minted shares were issued to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

Henry Schein declared that its Board of Directors has authorized a share buyback program on Tuesday, September 19th 2017, which authorizes the company to repurchase $400,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 6.3% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's management believes its shares are undervalued.

Henry Schein, Inc. (NASDAQ:HSIC) issued its quarterly earnings data on Tuesday, August, 8th. The company reported $0.88 earnings per share for the quarter, beating analysts' consensus estimates of $0.87 by $0.01. The company had revenue of $3.06 billion for the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a return on equity of 19.91% and a net margin of 4.59%. The firm's revenue for the quarter was up 6.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.82 earnings per share. View Henry Schein's Earnings History.

Henry Schein is scheduled to release their next quarterly earnings announcement on Tuesday, October, 31st 2017. View Earnings Estimates for Henry Schein.

Henry Schein updated its FY17 earnings guidance on Tuesday, August, 8th. The company provided EPS guidance of $7.17-7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.29.

15 analysts have issued 12-month target prices for Henry Schein's stock. Their forecasts range from $81.50 to $109.00. On average, they expect Henry Schein's stock price to reach $92.89 in the next year. View Analyst Ratings for Henry Schein.

Here are some recent quotes from research analysts about Henry Schein stock:

• 1. According to Zacks Investment Research, "Henry Schein exited second-quarter 2017 on a solid note with earnings and sales beating the Zacks Consensus Estimate. Apart from balanced growth across all its operating segments, Henry Schein's share gains in both the U.S. and overseas markets raise optimism. We are also positive about the company opening a National Distribution Service Center to strengthen its presence in central Ohio. On the flip side, over the last three months, the company has underperformed the broader industry. Also, despite the better-than-expected earnings, we are disappointed with the company’s unchanged EPS guidance for 2017. Meanwhile, Henry Schein’s venture in digital dentistry through DENTSPLY SIRONA deal may intensify its already weak operating margin scenario on escalating education and training expenses. Also, foreign currency fluctuations continued to mar the company’s financials." (8/9/2017)
• 2. Evercore ISI analysts commented, "HSIC continues to deliver consistent HSD to LDD EPS growth despite an operating environment that has been somewhat mixed, albeit North American Dental continues to show signs of recovery. With the acquisition engine still churning and an elevated level of buybacks, management has been able to deliver the type of TSR expected and thus the valuation remains notably elevated on an absolute basis (less so on a relative basis). While we also value consistency and predictability, we acknowledge we missed the November entry point (fears of US slowdown) and thus at current levels see risk / reward as more fully balanced (particularly with extra week headwind in 2017 + unfavorable Fx environment). Given this dynamic we reiterate our Hold rating and argue shares are now accurately pricing in the current operating environment. Thus we await another period of uncertainty prior to revisiting our long-term constructive view on shares." (2/21/2017)

Henry Schein saw a increase in short interest in the month of September. As of September 29th, there was short interest totalling 8,187,143 shares, an increase of 47.2% from the September 15th total of 5,562,584 shares. Based on an average daily volume of 1,754,214 shares, the days-to-cover ratio is presently 4.7 days. Currently, 5.3% of the shares of the stock are sold short.

Some companies that are related to Henry Schein include Essilor International SA (ESLOY), Zimmer Biomet Holdings (ZBH), Cerner Corporation (CERN), Incyte Corporation (INCY), C.R. Bard (BCR), Edwards Lifesciences Corporation (EW), Quintiles Transitional Holdings (Q), Cardinal Health (CAH), Mylan N.V. (MYL), Lonza Group Ag (LZAGY), AmerisourceBergen Corporation (Holding Co) (ABC), Smith & Nephew SNATS (SNN), Centene Corporation (CNC), Align Technology (ALGN), Eisai Co., Ltd (ESALY), Laboratory Corporation of America Holdings (LH), BioMarin Pharmaceutical (BMRN) and Teva Pharmaceutical Industries Limited (TEVA).

Henry Schein's management team includes the folowing people:

• Stanley M. Bergman, Chairman of the Board, Chief Executive Officer
• James P. Breslawski CPA, President, Director; Chief Executive Officer of Henry Schein Global Dental Group
• Steven Paladino CPA, Chief Financial Officer, Executive Vice President, Director
• Peter McCarthy, President of Global Animal Health Group
• David C. McKinley, President of Corporate Commercial Development Group, Chief Commercial Officer
• Bob Minowitz, President, International Dental Group, EMEA Region
• Bridget A. Ross, President of Global Medical Group
• Gerald A. Benjamin, Chief Administrative Officer, Executive Vice President, Director
• Mark E. Mlotek, Chief Strategic Officer, Executive Vice President, Director
• Karen N. Prange, Executive Vice President; Chief Executive Officer of Global Animal Health, Medical and Dental Surgical Group

Henry Schein's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Swedbank (1.49%), Fisher Asset Management LLC (0.53%), PGGM Investments (0.23%), Tesco Pension Investment Ltd (0.19%), Mountain Pacific Investment Advisers Inc. ID (0.17%) and Nationwide Fund Advisors (0.16%). Company insiders that own Henry Schein stock include Barry J Alperin, David Mckinley, Donald J Kabat, Gerald A Benjamin, James A Harding, Kurt P Kuehn, Lonnie Shoff, Lorelei Mcglynn, Louis W Sullivan, Mark E Mlotek, Michael Racioppi, Michael S Ettinger, Norman S Matthews, Paul Brons, Paul Rose, Peter M Mccarthy, Philip A Laskawy, Robert Minowitz, Stanley Komaroff, Stanley M Bergman and Steven Paladino. View Institutional Ownership Trends for Henry Schein.

Henry Schein's stock was bought by a variety of institutional investors in the last quarter, including Swedbank, Fisher Asset Management LLC, APG Asset Management N.V., PGGM Investments, Nationwide Fund Advisors, Mountain Pacific Investment Advisers Inc. ID, Shell Asset Management Co. and Tesco Pension Investment Ltd. View Insider Buying and Selling for Henry Schein.

Shares of Henry Schein can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Henry Schein stock can currently be purchased for approximately $82.85.